Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia

Completed

• Conditions: Leukemia

• Registration Number: NCT01139307
• Lead Sponsor: Children's Oncology Group

Brief Summary

RATIONALE: Studying samples of blood or tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in samples from patients with Down syndrome and acute megakaryoblastic leukemia.

Detailed Description

OBJECTIVES:

* Determine whether megakaryocyte differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor can lead to proliferation arrest, polyploidization, and terminal differentiation of blasts in specimens from patients with Down syndrome and acute megakaryoblastic leukemia.

OUTLINE: Cryopreserved specimens are cultured and treated in vivo (in mice) and in vitro with megakaryocytic differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor.

Study Timeline

• Study Start: 2009-07
• Study First Submitted: 2010-06-05
• Study First Submitted QC: 2010-06-05
• Study First Posted: 2010-06-08
• Primary Completion: 2012-08
• Status Verified: 2016-02
• Last Update Submitted: 2016-02-19
• Last Update Posted: 2016-02-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Terminal differentiation
Proliferation arrest
Polyploidization